Business Context and Reporting Period
Company: GAXOS.AI INC. (Ticker: GXAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2025
Business Overview: GAXOS.AI is a technology company developing AI applications across gaming, health, and wellness. Key segments include Gaxos Labs (generative AI for game developers), Gaxos Gaming (AI-integrated gaming platform with NFTs), and RNK Health (a 70% owned subsidiary providing non-clinical administrative services for telehealth). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Balance Sheet (Sept 30, 2025) |
|---|---|---|---|
| Revenues | $498,271 | $692,974 | - |
| Net Loss | $(1,140,873) | $(3,197,507) | - |
| Net Loss Attributable to Common Shareholders | $(1,001,474) | $(2,942,662) | - |
| Net Loss Per Share (Basic & Diluted) | $(0.14) | $(0.42) | - |
| Cash and Cash Equivalents | - | - | $914,183 |
| Short-Term Investments | - | - | $12,058,377 |
| Total Current Assets | - | - | $13,420,714 |
| Total Current Liabilities | - | - | $451,871 |
| Working Capital | - | - | $12,968,843 |
| Net Cash Used in Operating Activities | - | $(3,120,632) | - |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly from $2,704 in Q3 2024 to $498,271 in Q3 2025. This growth is primarily driven by RNK Health's administrative services, which generated $441,227 in the quarter. Subscription revenue from Gaxos Labs also contributed $57,042.
- Operating Expenses: Total operating expenses rose 99.5% year-over-year for the quarter to $1,813,026. Selling, general, and administrative (SG&A) expenses surged 134.6% to $1,539,005, largely due to a $781,011 increase in advertising and marketing fees for RNK Health services.
- Net Loss: Net loss increased 32.0% to $1,140,873 for the quarter, driven by higher operating costs outpacing revenue growth. However, the loss per share improved from $(0.61) to $(0.14) due to a significant increase in the weighted average shares outstanding (from ~1.4M to ~7.1M) following capital raises and warrant exercises in the prior year.
- Investment Portfolio: Short-term investments increased from $2.17 million at year-end 2024 to $12.06 million as of September 30, 2025, reflecting the deployment of capital raised in late 2024 into corporate bonds and funds.
Outlook, Risks, and Management Commentary
- Liquidity and Capital Resources: Management states that existing working capital ($12.97M) and cash on hand are sufficient to meet operating needs for the next 12 months. The company raised approximately $8.05 million in net proceeds from two registered direct offerings in December 2024.
- Strategic Focus: The company is accelerating development in Gaxos Health and RNK Health. RNK Health continues to partner with a third-party medical management company to provide telehealth support services.
- Risk Factors:
- Regulatory Risk: RNK Health's revenue is dependent on a Medical Partner subject to evolving state laws regarding telehealth and prescription practices. Changes in regulations could materially impact operations.
- Profitability: The company expects to continue generating operating losses in the foreseeable future due to corporate overhead, R&D, and public company costs.
- Financing: Future success depends on the ability to obtain additional financing if revenue generation does not meet capital requirements.
- Unusual Items: The company recorded a $10,000 note receivable from RPM Interactive, Inc. and issued 200,000 shares of common stock valued at $248,000 in exchange for intangible software assets in February 2025.
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of RNK Health revenue, which accounted for approximately 88% of Q3 2025 total revenue.
- Regulatory Compliance: Review the specific state-level regulatory risks associated with the Medical Partner's telehealth model as detailed in the Risk Factors section.
- Cash Burn Rate: Monitor the net cash used in operating activities ($3.12M for nine months) against the current cash and short-term investment balance to assess runway.
- Dilution: Note the significant increase in share count (from ~1.4M to ~7.1M) and the existence of ~4.5M outstanding warrants, which could impact future earnings per share.
- Intangible Assets: Review the amortization schedule for the $748,000 intangible asset acquired in February 2025, which will impact future operating expenses.